Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling. Elevidys ...

led by Sarepta's Elevidys (delandistrogene moxeparvovec), which has been cleared by the FDA for use in ambulatory and non-ambulatory DMD patients aged four and above. Vertex's gene-editing therapy ...

Their advice comes from personal experience. After entering into many tough conversations about money among themselves, friends and others, they buckled down and paid off $200,000 in debt, learned ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research ...

RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that included am Elevidys patient death, which occurred in November in a ...

Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease.

aMedical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil bGrupo de Pesquisa Clínica em Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil ...